Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
live attenuated varicella-zoster virus vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This live attenuated varicella-zoster virus (VZV) vaccine is a biologic developed for the prevention of herpes zoster (shingles) in adults aged 40 years and older. It was evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial (NCT04334577) involving approximately 25,000 to 30,000 participants in China's Zhejiang and Jiangsu provinces. The trial, sponsored by the Jiangsu Province Centers for Disease Control and Prevention and utilizing vaccine produced by Changchun Changsheng Biotechnology, reported a vaccine efficacy of 57.6% against the incidence of herpes zoster. The vaccine contains live attenuated VZV (at least 4.3 LgPFU per dose) and aims to boost cell-mediated immunity to prevent the reactivation of latent virus in the sensory ganglia, which is the underlying cause of neurocutaneous herpes zoster disease.
- Other names
- VZV vaccineherpes zoster vaccinelive attenuated VZV vaccine
Beyond the preview
Go deeper on live attenuated varicella-zoster virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on live attenuated varicella-zoster virus vaccine.